- Home
- Companies
- Medical / Health Care
- Clinical Services
- Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.
We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with major depressive disorder (MDD), while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward investigating REL-1017 for potential indications as adjunctive and monotherapy.
Company details
Find locations served, office locations.
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)